Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06132841 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese
A Phase 1 study of Healthy Participants, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
- 3
- Study locations
NCT06132841: Active Phase 1 study of Healthy Participants, sponsored by AstraZeneca.
NCT06132841 is a Phase 1 study of Healthy Participants that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 104 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (60% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06132841, a Phase 1 study of Healthy Participants, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
- 3
- Study locations
Study Summary
A study in healthy male and female participants of non-childbearing and childbearing potential who have overweight or obesity
Primary Outcome
The safety and tolerability of repeated subcutaneous (SC) doses of AZD6234 compared to placebo will be assessed.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD6234
Study Locations (3)
California
- Research Site - Glendale
Maryland
- Research Site - Brooklyn
Other
- Research Site - Osaka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2023-11-13 |
| Est. Completion | 2026-03-23 |
| Phase | Phase 1 |
What the registry record for NCT06132841 still lists
NCT06132841 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (60% higher).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06132841 reports a single indexed study location in California, Maryland, Other.
Frequently Asked Questions
What is clinical trial NCT06132841 about?
NCT06132841 is a clinical study titled "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese". A study in healthy male and female participants of non-childbearing and childbearing potential who have overweight or obesity
What is the current status of trial NCT06132841?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2023-11-13. Estimated completion is 2026-03-23.
What conditions does trial NCT06132841 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT06132841?
The interventions under investigation include: Placebo (DRUG), AZD6234 (DRUG).
Who is sponsoring clinical trial NCT06132841?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06132841 being conducted?
This trial has 3 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06132841's enrollment target sits among peer trials
104 19th of 119 higher than 101 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI